Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at… read more.
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to… read more.
Researchers report that early treatment of type 2 diabetes with tirzepatide leads to greater improvements over 2 years in blood sugar, body weight, and waist size than treatment… read more.
Eating foods that contain common preservative food additives may increase the risks of high blood pressure and cardiovascular disease, according to research published in the European Heart Journal [1] today… read more.
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing… read more.
Emergency Medicine & Intensive Care
A large, multi-center study led by Ann & Robert H. Lurie Children’s Hospital of Chicago derived “achievable benchmarks of care” (ABCs) using electronic health record data, which allows… read more.
A Kaiser Permanente study published by NEJM Catalyst Innovations in Care Delivery provides real-world data on a new approach to cervical cancer screening: giving patients the option to skip the… read more.
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research… read more.
Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing… read more.
New research presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey, shows that rapid weight loss (RWL) is much more effective than gradual weight… read more.
Current evidence does not support a causal link between the use of almost all antidepressants during pregnancy and an increased risk of neurodevelopmental disorders, including autism and attention-deficit/hyperactivity… read more.
BridgeBio Pharma, Inc. announced new data from the Phase III ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
